Form 4: Cocrystal Pharma Director Granted Stock Options

Cocrystal Pharma's Director, Richard C. Pfenniger Jr., was granted 16,410 non-qualified stock options with an exercise price of $1.1 under the 2025 Equity Incentive Plan.

Summary

• Richard C. Pfenniger Jr., a Director of Cocrystal Pharma, Inc. (COCP), received a grant of 16,410 non-qualified stock options.
• The options have an exercise price of $1.1 per share.
• The grant was made on January 9, 2026, under the company's 2025 Equity Incentive Plan.
• The options will vest in two stages: one-half on January 9, 2027, and the remaining half in eight equal quarterly installments commencing on March 31, 2027.
• Vesting is contingent upon Mr. Pfenniger's continued service as a director of the Issuer on each applicable vesting date.
• The options expire on January 9, 2036.

Sentiment

Score: 7

Explanation: This is a routine insider transaction reporting director compensation, which is generally a neutral to slightly positive signal as it indicates continued director involvement and alignment of interests with shareholders. It does not present significant positive or negative surprises.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Cocrystal Pharma, Inc.
• The transaction was approved by the Issuer's Compensation Committee of the Board of Directors, indicating proper corporate governance oversight.

Risks

• The exercisability and vesting of the non-qualified stock options are subject to the execution of the Issuer's form of Non-Qualified Stock Option Agreement.
• Vesting of the options is conditional on the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date, posing a risk if service is terminated.

Future Outlook

The grant of options under the 2025 Equity Incentive Plan suggests ongoing efforts to align director incentives with the company's long-term performance and strategic objectives. The vesting schedule encourages continued service and commitment from the director.

Management Comments

• The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors.

Industry Context

Granting equity incentives like stock options to directors is a common practice across various industries, including biotechnology, to attract, retain, and motivate key personnel. This aligns their interests with those of shareholders, encouraging long-term value creation. The structure of the grant, including the vesting schedule, is typical for such compensation plans.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, similar to companies like Gilead Sciences or Amgen, to incentivize long-term performance and retention.
• The vesting schedule, which includes a one-year cliff for half the options and subsequent quarterly vesting for the remainder, is a common structure designed to encourage sustained commitment and service, comparable to practices seen at many publicly traded companies.
• The exercise price being set at a specific value, typically at or above the market price on the grant date, is consistent with non-qualified stock option grants across the industry, ensuring the incentive is tied to future stock appreciation.

Corporate Governance

Related Party Transactions

• The grant of non-qualified stock options to Richard C. Pfenniger Jr., a director, constitutes a related party transaction, which is a standard form of director compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with long-term shareholder value, potentially leading to better governance and strategic decisions. However, it also represents potential future dilution upon exercise.
• Directors: Provides equity-based compensation, incentivizing continued service and performance tied to the company's stock price.

Next Steps

• Execution of the Issuer's form of Non-Qualified Stock Option Agreement by Richard C. Pfenniger Jr.
• Richard C. Pfenniger Jr. must continue to serve as a director for the options to vest.
• One-half of the options will vest and become exercisable on January 9, 2027.
• The remaining half of the options will vest in eight equal quarterly installments commencing on March 31, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a director as part of their compensation. It does not contain information that would fundamentally alter the investment thesis for Cocrystal Pharma, Inc. While it indicates continued director engagement and alignment of interests, it is not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should continue to hold and monitor the company's core business developments and financial performance.

Keywords

Cocrystal Pharma, COCP, Stock Options, Equity Incentive Plan, Director Compensation, Insider Transaction, Form 4, Non-qualified options, Vesting Schedule